Health
23 Oct 2026
Novartis drug cuts MS relapse rate by a third
In Phase 3 trials, remibrutinib lowered relapse rates by roughly a third compared to the standard drug Aubagio, while showing a cleaner safety profile.
Read moreTopic
#remibrutinib
1 story